Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

SZSE:002399 Stock Report

Market Cap: CN¥13.0b

Shenzhen Hepalink Pharmaceutical Group Future Growth

Future criteria checks 3/6

Shenzhen Hepalink Pharmaceutical Group is forecast to grow earnings and revenue by 65.9% and 6.5% per annum respectively. EPS is expected to grow by 65.9% per annum. Return on equity is forecast to be 6.1% in 3 years.

Key information

65.9%

Earnings growth rate

65.9%

EPS growth rate

Pharmaceuticals earnings growth18.8%
Revenue growth rate6.5%
Future return on equity6.1%
Analyst coverage

Low

Last updated15 Jul 2024

Recent future growth updates

Recent updates

Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt

Jun 12
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues

May 06
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues

Earnings and Revenue Growth Forecasts

SZSE:002399 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20266,545836N/AN/A1
12/31/20256,131779N/AN/A1
12/31/20245,673644N/AN/A1
3/31/20245,518-6951,0441,493N/A
12/31/20235,446-783-47398N/A
9/30/20235,827218-606-271N/A
6/30/20236,114340-1,314-1,059N/A
3/31/20236,550559-1,212-969N/A
1/1/20237,159727-979-757N/A
9/30/20227,129432-1,060-849N/A
6/30/20227,010414-722-513N/A
3/31/20227,008332-611-428N/A
1/1/20226,365241-200-7N/A
9/30/20216,42177796290N/A
6/30/20215,786781359548N/A
3/31/20215,198912484675N/A
12/31/20205,3321,024-17537N/A
9/30/20205,0281,097-456-206N/A
6/30/20205,1551,094-603-290N/A
3/31/20205,004808-634-307N/A
12/31/20194,6251,059-590-228N/A
9/30/20194,622812-483-9N/A
6/30/20194,736894-184304N/A
3/31/20194,8791,03069575N/A
12/31/20184,815591101636N/A
9/30/20184,307565-5472N/A
6/30/20183,905437-742-164N/A
3/31/20183,347278-1,155-500N/A
12/31/20172,843197N/A-486N/A
9/30/20172,486176N/A-404N/A
6/30/20172,218140N/A50N/A
3/31/20172,045189N/A226N/A
12/31/20162,261397N/A346N/A
9/30/20162,318466N/A436N/A
6/30/20162,279566N/A603N/A
3/31/20162,223590N/A694N/A
12/31/20152,292580N/A894N/A
9/30/20152,141532N/A936N/A
6/30/20152,251503N/A1,128N/A
3/31/20152,387453N/A1,029N/A
12/31/20141,959338N/A913N/A
9/30/20141,718250N/A726N/A
6/30/20141,477177N/A475N/A
3/31/20141,375249N/A513N/A
12/31/20131,513317N/A421N/A
9/30/20131,652436N/A303N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002399 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: 002399 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 002399 is expected to become profitable in the next 3 years.

Revenue vs Market: 002399's revenue (6.5% per year) is forecast to grow slower than the CN market (13.4% per year).

High Growth Revenue: 002399's revenue (6.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 002399's Return on Equity is forecast to be low in 3 years time (6.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y